<!DOCTYPE html>
<html>
  <head>
    <title>Osteoporosis</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/geriatrics/">geriatrics</a></li>
      <li class="active">Osteoporosis</li>
  </ol>

  <div class="page-header">
 
    <h1>Osteoporosis</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Osteoporosis</strong></a>
          <div class="toc">
<ul>
<li><a href="#risk-assessment">Risk assessment</a></li>
<li><a href="#bisphosphonates">Bisphosphonates</a><ul>
<li><a href="#risedronate">Risedronate</a></li>
<li><a href="#zoledronic-acid">Zoledronic acid</a></li>
<li><a href="#alendronate">Alendronate</a></li>
<li><a href="#adverse-effects">adverse effects</a></li>
</ul>
</li>
<li><a href="#calcium">calcium</a></li>
<li><a href="#vit-d">Vit D</a></li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <p>throughout lifetinme bone constantly remodelled</p>
<p>later in life resorption > formation —> bone loss</p>
<p>—> bone weakness and increase risk of fragility fractures</p>
<p>risk factors:</p>
<ul>
<li>
<p>frailty/immobilisation</p>
</li>
<li>
<p>low body weight</p>
</li>
<li>
<p>calcium deficient diet</p>
</li>
<li>
<p>history of smoking or etoh misuse</p>
</li>
</ul>
<p>peak bone mass achieved around age 30-35yo and then starts to decline</p>
<p>higher peak bone mass = lower impact of subsequent bone loss</p>
<p>not just disease of ageing:</p>
<ul>
<li>
<p>genetics</p>
<ul>
<li>
<p>euro > PI</p>
<ul>
<li>?due to life expectancy and lifestyle factors</li>
</ul>
</li>
</ul>
</li>
<li>
<p>lifestyle</p>
<ul>
<li>
<p>vit d def</p>
</li>
<li>
<p>excess vit a</p>
</li>
<li>
<p>low calicum intake</p>
</li>
<li>
<p>smoking</p>
</li>
<li>
<p>high etoh</p>
</li>
<li>
<p>lack of physcial activity</p>
</li>
<li>
<p>immobilisation</p>
</li>
<li>
<p>low body weight</p>
</li>
<li>
<p>execsie induced amenorrhea</p>
</li>
<li>
<p>falls</p>
</li>
</ul>
</li>
<li>
<p>hormones</p>
<ul>
<li>
<p>F>M</p>
</li>
<li>
<p>accelerated loss of bone density @ menopause</p>
<ul>
<li>decreasing oestrogen</li>
</ul>
</li>
<li>
<p>decrease testosterone, increase risk</p>
</li>
</ul>
</li>
<li>
<p>medical conditions:</p>
<ul>
<li>
<p>DM</p>
</li>
<li>
<p>IBD</p>
</li>
<li>
<p>RA</p>
</li>
<li>
<p>Anorexia</p>
</li>
</ul>
</li>
<li>
<p>Medicines:</p>
<ul>
<li>
<p>corticosteroids</p>
</li>
<li>
<p>PPI</p>
</li>
<li>
<p>excessive thyroid hormones</p>
</li>
<li>
<p>depo-medroxyprogesterone</p>
</li>
<li>
<p>MTX</p>
</li>
<li>
<p>anticonvulsants</p>
</li>
<li>
<p>lithium</p>
</li>
</ul>
</li>
</ul>
<p>all increase risk</p>
<ul>
<li>
<p>>50yo</p>
<ul>
<li>
<p>BMD 2.5 below young adult mean at femal neck</p>
<ul>
<li>T score ≤ 2.5</li>
</ul>
</li>
<li>
<p>elderly</p>
<ul>
<li>multiple hip or vertebral # in absence of major trauma</li>
</ul>
</li>
<li>
<p>in younger population</p>
<ul>
<li>Z score</li>
</ul>
</li>
<li></li>
</ul>
</li>
</ul>
<h3 id="risk-assessment">Risk assessment</h3>
<ul>
<li>
<p>DEXA scanning</p>
<ul>
<li>
<p>T score = young normal adult of same sex</p>
</li>
<li>
<p>Z score = expected for patient’s age and sex</p>
</li>
<li>
<p>T score = most predictive of future fracture </p>
</li>
<li>
<p>indicated for other people who have had an osteoprotoic fracutre except</p>
<ul>
<li>
<p>women >75yo</p>
</li>
<li>
<p>≥ 2 osteoporotic #</p>
</li>
<li>
<p>glucocotricoid >5mg for at least 3mo</p>
</li>
</ul>
</li>
<li>
<p>otherwise riks:</p>
<ul>
<li>
<p>female</p>
</li>
<li>
<p>low BMI</p>
</li>
<li>
<p>untreated premature menopause</p>
</li>
<li>
<p>fhx of maternal hip # \&lt;75yo</p>
</li>
<li>
<p>conditions affecting bone metaholism</p>
</li>
<li>
<p>chronic steroid use</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>FRAX</p>
<ul>
<li>
<p>includes risk factros:</p>
<ul>
<li>
<p>age</p>
</li>
<li>
<p>sex</p>
</li>
<li>
<p>ethnicity</p>
</li>
<li>
<p>height</p>
</li>
<li>
<p>BMNI</p>
</li>
<li>
<p>personal history fragility</p>
</li>
<li>
<p>fhx of hip #</p>
</li>
<li>
<p>glucocoticoid use</p>
</li>
<li>
<p>RA</p>
</li>
<li>
<p>other secondary causes</p>
</li>
</ul>
</li>
<li>
<p>BMD not required </p>
<ul>
<li>but is if want SA of alendronate or zolendronic acid</li>
</ul>
</li>
<li>
<p><a href="www.shef.ac.uk/FRAX/tool.aspx?country=23">nz calibrated FRAX</a></p>
</li>
</ul>
</li>
<li>
<p>Garvan fracture calculator</p>
<ul>
<li>
<p>10yr probability of patient experiencing fragility #</p>
</li>
<li>
<p>as or more effective than FRAX in healthy older women with noraml BMD</p>
</li>
<li>
<p>5 risk factrs:</p>
<ul>
<li>
<p>age</p>
</li>
<li>
<p>sex</p>
</li>
<li>
<p>falls last 12mo</p>
</li>
<li>
<p>weight</p>
</li>
<li>
<p>BMD measurements</p>
</li>
</ul>
</li>
<li>
<p><a href="http://garvan.org.au/promotions/bone-fracture-risk/calculator/">available here</a></p>
</li>
</ul>
</li>
</ul>
<h3 id="bisphosphonates">Bisphosphonates</h3>
<ul>
<li>
<p>bind to bone and reduce resorptive function of osteoclasts and accelerate osteosclast apoptosis</p>
</li>
<li>
<p>specific to bone</p>
<ul>
<li>40-60% of administered dose binds to bone and remainder excreted unmetabolised in urine</li>
</ul>
</li>
<li>
<p>reduce osteoporotic fractures</p>
<ul>
<li>
<p>vertebral risk reduction (post-menopausal women) = 40-70%</p>
</li>
<li>
<p>hip fracture = 40-50%</p>
</li>
</ul>
</li>
<li>
<p>lower fracture risk:</p>
<ul>
<li>
<p>increase bone mass</p>
</li>
<li>
<p>reduce rate of bone resorption</p>
</li>
</ul>
</li>
<li>
<p>BMD increase by approx. 5% following 2 years of treatment with potent bisphosphonate</p>
</li>
<li>
<p>clinical effective ness depends on:</p>
<ul>
<li>
<p>bone-binding affinity</p>
<ul>
<li>zolenndronic acid > alendronate > risedronate</li>
</ul>
</li>
<li>
<p>level of inhibition of key enzyme</p>
<ul>
<li>aolendronic acid > risedronate > alendronate</li>
</ul>
</li>
</ul>
</li>
<li>
<p>however; not possible as no head-head trials to state one is better than otherre reducing osteoporotic fracture risk</p>
<ul>
<li>although everything better than etridronate</li>
</ul>
</li>
</ul>
<h4 id="risedronate">Risedronate</h4>
<ul>
<li>
<p>fully subsidised</p>
<ul>
<li>doens’t require special authority</li>
</ul>
</li>
<li>
<p>more effective compared to etidronate</p>
<ul>
<li>simpler than cyclical dosing regime</li>
</ul>
</li>
<li>
<p>indications</p>
<ul>
<li>
<p>osteoporosis</p>
</li>
<li>
<p>post-menopausal osteoporosis</p>
</li>
<li>
<p>prevention of glucocorticoid induced osteoposrosis</p>
</li>
</ul>
</li>
<li>
<p>long term glucocorticoids</p>
<ul>
<li>
<p>≥7.5mg daily for more than 3mo with following risk factors are likely to beneft from risedronate</p>
<ul>
<li>
<p>≥ 65yo</p>
</li>
<li>
<p>\&lt;65yo with previous fragility #</p>
</li>
<li>
<p>\&lt;65yo without previous fragility # but T-score ≤ -1.5</p>
</li>
</ul>
</li>
<li>
<p>ideally DEXA should be requested</p>
<ul>
<li>
<p>if bisphosphonate treatment not indicated</p>
<ul>
<li>
<p>(t-score 0 and -1.5)</p>
<ul>
<li>DEXA repeated 1-3yr time</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>significantly better compared to placebo</p>
<ul>
<li>
<p>secdonary prevention of osteoporotic fractures</p>
</li>
<li>
<p>only small numbers included in primary prevention trial</p>
</li>
</ul>
</li>
<li>
<p>reduce:</p>
<ul>
<li>
<p>vertebral #: 41-49%</p>
</li>
<li>
<p>non vertebral 36%</p>
</li>
</ul>
</li>
<li>
<p>genearlly well tolerated</p>
</li>
<li>
<p>upper GI symptoms main adverse effet</p>
</li>
<li>
<p>risedronate = alendronate at reducing fracture risk</p>
</li>
<li>
<p><strong>prescribing</strong></p>
<ul>
<li>
<p>review diet and ensure calcium/vit D ok</p>
</li>
<li>
<p>CI</p>
<ul>
<li>
<p>contraindicated in hypocalcaemia</p>
</li>
<li>
<p>no prescribed eGFR \&lt; 30-35</p>
</li>
<li>
<p>avoided during pregnancy</p>
</li>
<li>
<p>oral formulations used with caution in any patient wiht oesophageal abnormal </p>
<ul>
<li>or any condition affects eptying of stomach</li>
</ul>
</li>
</ul>
</li>
<li>
<p>35mg once weekly</p>
<ul>
<li>
<p>full glass of water in morning after getting out of bed</p>
<ul>
<li>
<p>30min before any food or other liquids</p>
</li>
<li>
<p>should sit upright or stand 30mins afterwards</p>
<ul>
<li>reduce risk of oesophageal complications</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>initially prescribed for 3-5yrs</p>
<ul>
<li>
<p>re-assessmenet of BMD and of interval # history</p>
</li>
<li>
<p>majority of beneift in first 5yrs of treatment</p>
</li>
<li>
<p>drug holidays</p>
<ul>
<li>
<p>allow bone resportpion to recover</p>
</li>
<li>
<p>reduce risk of rare adverse effects</p>
</li>
</ul>
</li>
<li>
<p>if BMD > -2.0 @ femoral neck after 3-5yrs then most likely to benefit from holiday</p>
</li>
<li>
<p>reassess yearly</p>
</li>
</ul>
</li>
</ul>
<h4 id="zoledronic-acid">Zoledronic acid</h4>
<ul>
<li>
<p>special authority:</p>
<ul>
<li>
<p>1 significant previous osteoporotic fracture and T-score ≤ -2.5</p>
</li>
<li>
<p>1 osteoporotic fracture in older patient or in patient where DEXA cannot be reasonably performed</p>
</li>
<li>
<p>history of 2 osteoporotic fractures </p>
</li>
<li>
<p>T score ≤ -3.0</p>
</li>
<li>
<p>10yr hip facture risk ≥ 3% incorporating BMD</p>
</li>
<li>
<p>previous SA for treatmetn of osteoposrosis</p>
</li>
<li>
<p>has received or will be systemic corticosteroid equiv. ≥5mg prednisone and has one of:</p>
<ul>
<li>
<p>T scre ≤ -1.5</p>
</li>
<li>
<p>1 osteoporotic #</p>
</li>
<li>
<p>previous SA</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>once yearly</p>
</li>
<li>
<p>slow IV infusion over 30minutes</p>
</li>
<li>
<p>cannot be given CrCl \&lt;35</p>
</li>
<li>
<p>should be sufficiently hydrated prior</p>
</li>
<li>
<p>CI - hypocalcaemia</p>
<ul>
<li>
<p>check</p>
<ul>
<li>
<p>calcium</p>
</li>
<li>
<p>esp</p>
<ul>
<li>
<p>vit d def</p>
</li>
<li>
<p>undergone thyroid/parathyroid surgery</p>
</li>
<li>
<p>calcium malabsorption</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>paget’s</p>
<ul>
<li>
<p>need adequate calcium and vit d</p>
<ul>
<li>may benefit from calcium supp. for 2 weeks follwoing infusion</li>
</ul>
</li>
</ul>
</li>
<li>
<p>some patients may complain of flu-like illness</p>
<ul>
<li>
<p>relieved by paracetamol with 500mL water follwoing infusion</p>
</li>
<li></li>
</ul>
</li>
</ul>
<h4 id="alendronate">Alendronate</h4>
<ul>
<li>
<p>special authority:</p>
<ul>
<li>
<p>1 significant previous osteoporotic fracture and T-score ≤ -2.5</p>
</li>
<li>
<p>1 osteoporotic fracture in older patient or in patient where DEXA cannot be reasonably performed</p>
</li>
<li>
<p>history of 2 osteoporotic fractures </p>
</li>
<li>
<p>T score ≤ -3.0</p>
</li>
<li>
<p>10yr hip facture risk ≥ 3% incorporating BMD</p>
</li>
<li>
<p>previous SA for treatmetn of osteoposrosis</p>
</li>
<li>
<p>has received or will be systemic corticosteroid equiv. ≥5mg prednisone and has one of:</p>
<ul>
<li>
<p>T scre ≤ -1.5</p>
</li>
<li>
<p>1 osteoporotic #</p>
</li>
<li>
<p>previous SA</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="adverse-effects">adverse effects</h4>
<ul>
<li>
<p>gastrointestinal disturbance</p>
<ul>
<li>
<p>oesophagitis</p>
</li>
<li>
<p>abdominal pain</p>
</li>
<li>
<p>dyspepsia</p>
</li>
<li>
<p>diarrhoea</p>
</li>
<li>
<p>constipation</p>
</li>
<li>
<p><strong>discontinue</strong> if:</p>
<ul>
<li>
<p>difficulty/pain on swallowing</p>
</li>
<li>
<p>chest pain</p>
</li>
<li>
<p>heart burn</p>
</li>
</ul>
</li>
<li>
<p>consider zoledronic acid</p>
</li>
</ul>
</li>
<li>
<p>headache</p>
</li>
<li>
<p>msk pain</p>
</li>
<li>
<p>osteonecrosis of jaw</p>
<ul>
<li>
<p>rare</p>
</li>
<li>
<p>1/100 000 - 250 000 people</p>
</li>
<li>
<p>no evdiecne that any more common in people taking bisphosphonate for osteoporiss than it is in people with osteoporosis not using these medicines</p>
</li>
<li>
<p>associated with high doses of IV bisphosphonates for cancer treatment</p>
</li>
<li>
<p>ppt. by dental extraction or oral surgery</p>
</li>
<li>
<p>additional factors:</p>
<ul>
<li>
<p>poor oral hygiene</p>
</li>
<li>
<p>poorly fitting dental appliances</p>
</li>
<li>
<p>intra-oral trama</p>
</li>
<li>
<p>use of corticosteroids</p>
</li>
<li>
<p>dm</p>
</li>
<li>
<p>etoh </p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>atypical femur #</p>
<ul>
<li>
<p>5-7yrs of bisphosphonate treatment</p>
</li>
<li>
<p>located;</p>
<ul>
<li>subtrochanteric/shaft regions of femur</li>
</ul>
</li>
<li>
<p>radiological characteristics of stress or fatigue #</p>
</li>
<li>
<p>rare - \&lt;1%</p>
</li>
<li>
<p>+ glucocorticoids / PPI</p>
</li>
</ul>
</li>
<li>
<p>ocular inflammation</p>
<ul>
<li>
<p>uveitis</p>
</li>
<li>
<p>scleritis</p>
</li>
<li>
<p>= very rare</p>
</li>
</ul>
</li>
<li>
<p>all patients should be monitiroed druing treatment for hypocalcaemia with:</p>
<ul>
<li>
<p>intercurrent illness</p>
</li>
<li>
<p>renal impairment</p>
</li>
<li>
<p>hypoparathyroidism</p>
</li>
<li>
<p>hypocalcaemia</p>
</li>
</ul>
</li>
</ul>
<h3 id="calcium">calcium</h3>
<ul>
<li>
<p>intake needs to be adequate throughout person’s life</p>
</li>
<li>
<p>700-1000mg / day</p>
</li>
<li>
<p>calcium rich food = 300mg</p>
<ul>
<li>
<p>250mL mild</p>
</li>
<li>
<p>40g cheese (2-3 slices cheddar)</p>
</li>
<li>
<p>half cup of tofu</p>
</li>
<li>
<p>1 cup mussels</p>
</li>
<li>
<p>100g canned salmon with bones</p>
</li>
<li>
<p>1 pottle of yoghurt = 200mg</p>
</li>
<li>
<p>half cup almonds (raw) = 200mg</p>
</li>
</ul>
</li>
<li>
<p>calcium supplementation should not routinely be prescribed to patients at increase risk fo fractures</p>
<ul>
<li>may be required if dietary intake is insufficient</li>
</ul>
</li>
<li>
<p>excessive supplementation should be avoided (>1000mg/day)</p>
<ul>
<li>increase risk of kidney stones and soft-tissue calcification</li>
</ul>
</li>
<li>
<p>some evidence calcium supplementation = adverse cardiovascular effects</p>
<ul>
<li>debate</li>
</ul>
</li>
<li>
<p>calicum interferes wiht absorption of bisphosphonates and should be taken at different tie of the day</p>
</li>
</ul>
<h3 id="vit-d">Vit D</h3>
<ul>
<li>
<p>synthsised in skin</p>
</li>
<li>
<p>sufficient exposure to UVB in sunlight </p>
<ul>
<li>
<p>15-20min of sun exposure to face and arms</p>
</li>
<li>
<p>dark skin = 3-4x more</p>
</li>
<li>
<p>allow healthy person to meet daily vit d requirement</p>
</li>
</ul>
</li>
<li>
<p>however</p>
<ul>
<li>
<p>dark pigmentation</p>
</li>
<li>
<p>olderpeople</p>
</li>
</ul>
</li>
<li>
<p>systematic review</p>
<ul>
<li>
<p>unlikley to be of benefit for osteoporosis prevention alone </p>
</li>
<li>
<p>unless specific risk factors for vit d def</p>
<ul>
<li>
<p>frail elderly housebound</p>
</li>
<li>
<p>1.25mg cholecalciferol monthly</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>testing of vit D levels not necessary</strong></p>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
